QP 12 - Sarcoma 2: Advancing Treatment Frontiers in Cutaneous Malignancies and Sarcoma

Moderator(s)

• CB

  Christopher Barker, MD

  Memorial Sloan Kettering Cancer Center
  New York, NY, United States
• PC

  Peter Chung, MB, ChB, FRCPC

  Princess Margaret Cancer Centre
  Toronto, ON, Canada

Presentations:

• 2:30 PM – 2:35 PM ET

  Introduction
• 2:35 PM – 2:40 PM ET

  Adjuvant Primary Site Radiation Therapy for Melanoma in the Immunotherapy Era
  

  Presenter: Andrew Arifin, MD – London Health Sciences Centre
• 2:40 PM – 2:45 PM ET

  Evaluation of Genomic and Pathologic Features Associated with Outcomes among Patients with Sentinel Lymph Node-Positive Melanoma in the Contemporary Era
  

  Presenter: Stephanie Dudzinski, MD, PhD – MD Anderson Cancer Center
• 2:45 PM – 2:50 PM ET

  Hypofractionated Radiation Therapy for Unresectable or Bulky Metastatic Melanoma
  

  Presenter: Devarati Mitra, MD, PhD – MD Anderson Cancer Center
• 2:50 PM – 2:55 PM ET

  Preoperative Hypofractionated Radiotherapy with Locoregional Hyperthermia in Recurrent and Radiation-Associated Sarcomas: Final Results of a Phase 2 Clinical Trial
  

  Presenter: Mateusz Spałek, MD, DSc, PhD, MBA – Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie – Panstwowy Instytut Badawczy w Warszawie
• 2:55 PM – 3:00 PM ET

  Long-Term Outcomes following Proton-Based Radiation Therapy for Pediatric Chordomas and Chondrosarcomas of the Mobile Spine and the Sacrum
  

  Presenter: Myrsini Ioakeim-Ioannidou, MD – Massachusets General Hospital
• 3:00 PM – 3:05 PM ET

  Use of the 40-Gene Expression Profile (40-GEP) Test to Identify Immune Suppressed Patients with Brigham and Womens Hospital (BWH) T1-T2a Cutaneous Squamous Cell Carcinoma (cSCC) at Higher Risk of Meta
  

  Presenter: Shlomo Koyfman, MD – Cleveland Clinic Foundation
• 3:05 PM – 3:25 PM ET

  Questions and Answers
• 3:25 PM – 3:30 PM ET

  Closing